Arena Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
SAN DIEGO, April 5, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
on Wednesday, April 11, 2007 at 9:45 a.m. Eastern Time (6:45 a.m. Pacific
Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's
President and Chief Executive Officer, is scheduled to provide a corporate
overview of the company and its clinical development and discovery programs.
A live audio webcast of the presentation will be available under the
investor relations section of Arena's website at www.arenapharm.com. A replay
of the presentation will be available for 30 days following the event. Please
connect to Arena's website several minutes prior to the start of the webcast
to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory, and
metabolic diseases. Arena's most advanced product candidate, lorcaserin, is
being investigated in a Phase 3 clinical trial program for the treatment of
obesity. Arena's broad pipeline of novel compounds targeting G
protein-coupled receptors, an important class of validated drug targets,
includes compounds being evaluated independently and with its partners, Merck
& Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, preclinical and internal
and partnered clinical programs, and ability to develop compounds and
commercialize drugs. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking statements
include, but are not limited to, Arena's planned clinical trials may not
proceed at the time Arena expects or at all, the results of preclinical
studies or clinical trials may not be predictive of future results, Arena's
ability to partner lorcaserin, APD125, APD791 or other of its compounds or
programs, the timing, success and cost of Arena's research, out-licensing
endeavors and clinical trials, Arena's ability to obtain additional financing,
Arena's ability to obtain and defend its patents, and the timing and receipt
of payments and fees, if any, from Arena's collaborators. Additional factors
that could cause actual results to differ materially from those stated or
implied by Arena's forward-looking statements are disclosed in Arena's filings
with the Securities and Exchange Commission. These forward-looking statements
represent Arena's judgment as of the time of this release. Arena disclaims
any intent or obligation to update these forward-looking statements, other
than as may be required under applicable law.
SOURCE Arena Pharmaceuticals, Inc.
Jack Lief, President and CEO, or David Walsey, Director, Corporate Communications,
both of Arena Pharmaceuticals, Inc., +1-858-453-7200, ext. 1682; or E. Blair Schoeb,
Media Relations of WeissComm Partners, +1-760-365-1857, for Arena Pharmaceuticals,